Search

Search Constraints

You searched for: Author/Creator Lisby, Steen

Search Results

1. A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B‐cell lymphoma. (23rd August 2013)

2. Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. Issue 2 (1st February 2017)

3. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Issue 9980 (9th May 2015)

4. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Issue 10027 (9th April 2016)

5. Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL. Issue 7 (3rd July 2017)

6. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Issue 13 (October 2015)

7. Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Issue 5 (4th May 2017)

8. Ofatumumab retreatment and maintenance in fludarabine‐refractory chronic lymphocytic leukaemia patients. (30th March 2015)

9. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Issue 1 (January 2017)

10. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Issue 9 (1st September 2016)